

F. No. ND/MA/23/000113
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

Tele No.011-23236965
Fax.No.011-23236973

FDA Bhawan, Kotla
Road,
New Delhi-11 0002
Dated:

To
M/s Sun Pharmaceutical Industries Limited,
Tandalja, Vadodara, Gujarat—390012.

Subject: Application for permission to conduct " A Prospective, Randomized, Multi-Center, Parallel-Group, Assessor-Blind, Active-Controlled, Phase III Study to Assess the Efficacy and Safety of Fixed Dose Combination of Relugolix, Estradiol, and Norethindrone Acetate in Comparison to Leuprolide in Heavy Menstrual Bleeding Associated With Uterine Fibroids"(Protocol no. ICR/23/001, Version no. 1; Dated: 21/APR/2023-regarding.

Sir,

With reference to your application no. ND/CT21/FF/2023/38558 & letter no. SPILMR/07/58A dated 14.07.2023; please find enclosed herewith the permission in **Form CT-06 vide No. CT/ND/05/2024** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

This permission is subject to the conditions, as mentioned below.

RAJEEV SINGH
RAGHUVANS
HI
Yours faithfully

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD
CONTROL ORGANIZATION, ou=RAJEEV SINGH
RAGHUVANSHI, email=rajeev.singh@cdso.gov.in, serialNumber=600034, st=TAMIL NADU,
postalCode=600034, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2024.04.25 17:09:50 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority

Conditions of permission

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;

- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty

- working days of the receipt of order issued by Central Licencing Authority in *accordance* with the provisions of the said Chapter;
- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
 - (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorized by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
 - (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
 - (xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
 - (xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
 - (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
 - (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG**

The Central Licensing Authority hereby permits **M/s Sun Pharmaceutical Industries Limited, Tandalja, Vadodara, Gujarat—390012. Tel.: (91-265) 661 5500 Fax : (91-265) 235 4897 E-Mail : IRA@SUNPHARMA.COM** to conduct clinical trial of the new drug as per Protocol Number: **ICR/23/001, Version no. 1; Dated: 21/APR/2023** in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:

Names of the new drug or investigational new drug:		Relugolix, Estradiol and Norethindrone Acetate Tablets (40 mg + 1 mg + 0.5 mg)
Therapeutic class:		Gonadotropin releasing hormone receptor antagonist
Dosage form:		Tablets
Composition:		Each film coated tablet contains: Relugolix....40 mg Estradiol Hemihydrate IP.....1 mg Norethindrone Acetate USP.....0.5 mg Excipients....q.s. Colours: Ferric Oxide (Yellow) USP-NF and Titanium Dioxide IP
Indications:		Indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women
Details of clinical trial sites-		
Sr. No.	Name of Principal Investigator & Trial Sites	Ethics Committee Name/ Registration Number
1.	Dr. Deepa Chaudhary (Associate Professor) Department of Obstetrics & Gynaecology, SMS Medical College and attached Hospital, Jaipur	Ethics Committee, S.M.S. Medical College and attached Hospitals, Jaipur ECR/26/Inst/RJ/2013/RR-19
2.	Dr. Neena Gupta (Professor and Head of department) Department of Gynecology, GSVM Medical College, Kanpur	Ethics Committee GSVM Medical College, Kanpur ECR/680/Inst/UP/2014/RR-20
3.	Dr. Palve Tushar Tatyaba (Associate Professor) Cama And Albless Hospital, Mumbai (Maharashtra)	IEC of New Health Care Nursing Home, Thane (Maharashtra) ECR/1388/Inst/MH/2020
4.	Dr. Rani Kumari L (Assistant Professor)	Institutional Ethics Committee Gandhi Medical College and Hospital,

	Department of Obstetrics & Gynecology, Gandhi Hospital, Secunderabad	Secunderabad ECR/180/Inst/AP/2013/RR-19
5.	Dr. Sangeeta Rai (Professor) Department of Obstetrics & Gynaecology, Institute of Medical Sciences, Banaras Hindu University, Varanasi	Institutional Ethics Committee, Institute of Medical Sciences, Banaras Hindu University, Varanasi ECR/526/Inst/UP/2014/RR-20
6.	Dr. P. Malathi (Professor) Department of Obstetrics & Gynaecology, Modern Government Maternity Hospital, Hyderabad	Institutional Ethics Committee, Osmania Medical College, Hyderabad ECR/35/Inst/WB/2013/RR-19
7.	Dr. Gaurisankar Kamilya (Professor) Department of Gynaecology and Obstetrics, IPGME&R and SSKM Hospital, Kolkata	IPGME and R Research Oversight Committee, Kolkata ECR/35/Inst/WB/2013/RR-19
8.	Dr. Isukapalli Vani (Professor) Department of Gynecology, King George Hospital, Visakhapatnam	IEC King George Hospital, Visakhapatnam ECR/197/Inst/KGH/2013/RR-20
9.	Dr. Jasmina Begum (Assistant Professor) Department of Obstetrics and Gynecology, AIIMS, Bhubaneswar	Institutional Ethics Committee, AIIMS, Bhubaneswar ECR/534/Inst/OD/2014/RR-20
10.	Dr. Kamlesh Kumari (Associate Professor) Department of Obstetrics and Gynecology, Jaipur National University Institute for Medical Sciences and Research Centre, Jaipur	Institutional Ethics Committee, JNU Institute for Medical Sciences and Research Centre, Jaipur ECR/905/Inst/RJ/2017/RR-20
11.	Dr. Roopa N. K (Professor) Department of Obstetrics and Gynecology, BGS Global Institute of Medical Sciences, Bangalore	Department of Obstetrics and Gynecology, BGS Global Institute of Medical Sciences, Bangalore ECR/1307/Inst/KA/2019
12.	Dr. Sweety Saigal (Consultant) Department of Gynecology, Brij Medical Centre Pvt Ltd, Kanpur	Ethics Committee Brij Medical Centre Pvt Ltd, Kanpur ECR/642/Inst/UP/2014/RR-20
13.	Dr. Kanika Jain (Senior Consultant Obstetrics & Gynaecology) Sir Ganga Ram Hospital, New Delhi	Sir Ganga Ram Hospital Ethics Committee, New Delhi ECR/20/Inst/DL/2013/RR-19
14.	Dr. Pendse Bakul Vijay (Consultant Obstetrics & Gynecologist)	Ethics Committee Deoyani Multispecialty Hospital, Pune ECR/1298/Inst/MH/2019

	Deoyani Multispecialty Hospital, Pune	
15	Dr. Usha Vishwanath (Professor) Sri Ramachandra Hospital, Chennai	Institutional Ethics Committee SRIHER, Chennai ECR/203/Inst/TN/2013/RR-19
16	Dr. Shalini Srivastava (Consultant Gynecologist) OM Surgical Centre & Maternity Home, Varanasi	IEC-Om Surgical Center and Maternity Home, Varanasi ECR/628/Inst/UP/2014/RR-20
17	Dr. Vidya V Bhat (Medical Director) Radhakrishna Multispecialty Hospital and IVF Centre, Bangalore	Institutional Ethics Committee, BGS Global Institute of Medical Sciences, Bangalore ECR/1307/Inst/KA/2019
18	Dr. Kartikbhai Pravinbhai Savalia (Consultant Obstetrics & Gynecologist) Department of Gynaecology, Priyadarshani Nursing Home, Palghar (Maharashtra)	IEC of New Health Care Nursing Home, Thane (Maharashtra) ECR/1388/Inst/MH/2020

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

**RAJEEV SINGH
RAGHUVANSHI**

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL
ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI,
2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c276904
1015a06564fe67f54b765db1cb, postalCode=600034,
st=TAMIL NADU,
serialNumber=657F5E47D940985D8F03BDC902D0E1F
E73CFAT2A1A126EA94FA5701124A19013, cn=RAJEEV
SINGH RAGHUVANSHI
Date: 2024.04.25 17:10:07 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority
Stamp

New Delhi

Date: